All > Adenocarcinoma > Hepatocellular Carcinoma

CT-0508 for HER2-positive Breast Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
HER2-positive Breast Cancer+33 MoreCT-0508 - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new cancer treatment involving CAR macrophages (a type of white blood cell) and HER2 overexpressing solid tumors (a type of cancer).

Eligible Conditions
  • HER2-positive Breast Cancer
  • Ovarian Cancer
  • Small Cell Carcinoma
  • Squamous Cell Carcinoma
  • Endometrial Cancer
  • Biliary Tract Cancer
  • Breast Cancer
  • Inflammatory Breast Cancer
  • Small Cell Lung Cancer
  • Ovarian Tumors
  • Cholangiocarcinoma
  • Colorectal Cancer
  • Cancer
  • HER2 Positive
  • HER2 Positive Breast Cancer
  • Transitional Cell Carcinoma
  • Stomach Tumors
  • Head and Neck Cancer
  • Hepatocellular Carcinoma
  • Prostate Cancer
  • Adenocarcinoma
  • Bladder Cancer
  • Non-Small Cell Lung Cancer
  • Esophagogastric Junction Cancer
  • Ductal Carcinoma
  • Pancreatic Cancer
  • HER2 Positive Gastric Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
89Zr-ss-pertuzumab PET/CT
1
SGN-B7H4V
1
SGN-ALPV

Study Objectives

3 Primary · 2 Secondary · Reporting Duration: 24 months

12 months
Assess the feasibility of manufacturing CT-0508 by describing the percentage of products passing release criteria.
14 months
Assess the safety and tolerability of CT-0508 by estimating the frequency and severity of adverse events in subjects with HER2 overexpressing solid tumors.
Assess the safety and tolerability of CT-0508 in combination with pembrolizumab by estimating the frequency and severity of adverse events in subjects with HER2 overexpressing solid tumors (CT-0508 and pembrolizumab substudy only)
24 months
Estimate progression-free survival (PFS).
Estimate the objective response rate (ORR), according to RECIST v1.1, of at least 1 dose of CT-0508 among subjects with HER2 overexpressing solid tumors.

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
89Zr-ss-pertuzumab PET/CT
1
SGN-B7H4V
1
SGN-ALPV

Side Effects for

Pembrolizumab Second Course
100%Parkinsonism
100%Urinary tract infection
100%Inappropriate antidiuretic hormone secretion
This histogram enumerates side effects from a completed 2021 Phase 3 trial (NCT03066778) in the Pembrolizumab Second Course ARM group. Side effects include: Parkinsonism with 100%, Urinary tract infection with 100%, Inappropriate antidiuretic hormone secretion with 100%.

Trial Design

4 Treatment Groups

89[Zr]radiolabeled CT-0508
1 of 4
Intraperitoneal Administration
1 of 4
CT-0508 in Combination with Pembrolizumab
1 of 4
Group 1 and Group 2
1 of 4

Experimental Treatment

48 Total Participants · 4 Treatment Groups

Primary Treatment: CT-0508 · No Placebo Group · Phase 1

89[Zr]radiolabeled CT-0508
Biological
Experimental Group · 1 Intervention: CT-0508 · Intervention Types: Biological
Intraperitoneal Administration
Biological
Experimental Group · 1 Intervention: CT-0508 · Intervention Types: Biological
CT-0508 in Combination with PembrolizumabExperimental Group · 2 Interventions: Pembrolizumab, CT-0508 · Intervention Types: Biological, Biological
Group 1 and Group 2
Biological
Experimental Group · 1 Intervention: CT-0508 · Intervention Types: Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
2017
Completed Phase 3
~2240

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 24 months

Who is running the clinical trial?

Carisma Therapeutics IncLead Sponsor
Debora Barton, MDStudy DirectorCarisma Therapeutics
2 Previous Clinical Trials
1,075 Total Patients Enrolled
Ramona Swaby, MDStudy DirectorCarisma Therapeutics

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have HER2-positive recurrent or metastatic solid tumors for which there are no curative treatments currently available.
Your breast cancer or gastric/gastroesophageal junction cancers have not responded to HER2-targeted treatments.
Other HER2-positive tumor types must have had unsuccessful responses to conventional treatments, although prior usage of anti-HER2 medications is not mandatory.
You are willing and capable of undergoing a tumor biopsy.
Your ECOG performance status is 0 or 1.
You possess satisfactory bone marrow and organ functioning.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top